Radnostix Reports Q3 FY2026 Results With 15% Theranostics Sales Gain
Radnostix posts rising theranostics revenue, agrees to sell fluorine assets, and files a key drug master file for a radioactive iodine therapy ingredient.
Radnostix, Inc., the Idaho Falls-based radioisotope manufacturer formerly known as International Isotopes Inc. and traded on the OTCQB under the ticker INIS, reported its third-quarter and nine-month financial results for fiscal year 2026, disclosing a 15% year-over-year increase in theranostics sales — a segment that combines diagnostic imaging with targeted therapy using radioactive compounds.
Alongside the revenue update, the company announced it has signed an agreement to divest its fluorine products and depleted uranium hexafluoride, or DUF6, assets to Nano Nuclear Energy. The divestiture signals a strategic narrowing of focus for Radnostix as it moves away from industrial fluorine chemistry and toward higher-margin medical isotope applications.
Read more Florida Housing Sales Dip in October as Mortgage Rates Bite →
The company also disclosed it has submitted a Type II Drug Master File, known as a DMF, to U.S. regulators for its Sodium Iodide I-131 active pharmaceutical ingredient. A DMF submission is a standard regulatory step that allows a manufacturer to provide confidential technical information to the FDA in support of drug product approvals by third-party customers, potentially broadening Radnostix's commercial reach in the radioiodine therapy market.
Together, the financial results, asset sale, and regulatory filing paint a picture of a small-cap nuclear medicine company repositioning itself around theranostics and radiopharmaceutical supply at a moment when the broader sector is drawing increased investor and clinical attention. The theranostics market has expanded rapidly as oncology treatments based on targeted radiotherapy gain regulatory acceptance.
Continue reading at Earnings for the full financial tables and management commentary.